Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis

doi:10.3748/wjg.v18.i5.466

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 5

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3464)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

319

HTML

2743

Figures (1-1)

200

Tables (1-4)

202

Sum=3464

Feb 7, 2012 (publication date) through Nov 4, 2024

Times Cited of This Article

Times Cited (6)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 7, 2012; 18(5): 466-471
Published online Feb 7, 2012. doi: 10.3748/wjg.v18.i5.466

Open in New Tab Full Size Figure Download Figure

Figure 1 Kaplan-Meier analysis of the survival time in all advanced hepatocellular carcinoma patients (A), in the subgroup of disease stabilization (B), and in the subgroup of > 50% decrease in alpha fetoprotein (C). CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; AFP: Alpha fetoprotein.

Citation: Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: A retrospective analysis. World J Gastroenterol 2012; 18(5): 466-471
URL: https://www.wjgnet.com/1007-9327/full/v18/i5/466.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i5.466